China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Qu...(w CFO and the new independent director D...),Health

Date:11/20/2008

w CFO and the new independent director Dr. Jason Zhang, who is also on our Audit Committee, is to bring their expertise in accounting, auditing, corporate governance and reporting to help restore shareholders' confidence. These steps should result in substantial improvement in our financial reporting process."

Restatement Impact on Full-Year 2007 and First Quarter 2008

    The summarized restated results for 2007 and first quarter 2008 are as
follows:

    Full Year 2007             As Previously Reported     As Restated
    Net Income (Loss)               $4,016,640             $1,720,387
    Net Income (Loss)
     Per Diluted Share                    0.21                   0.09

    First Quarter 2008         As Previously Reported     As Restated
    Net Income (Loss)                ($338,341)             ($852,660)
    Net Income (Loss)
     Per Diluted Share                   (0.02)                 (0.04)

More detail regarding these amounts and the restatements can be obtained from the Company's amended Annual Report on Form 10-KSB/A for the year ended December 31, 2007, and its amended Quarterly Report on Form 10-Q/A for the first quarter ended March 31, 2008, which were filed with the U.S. Securities and Exchange Commission on Friday November 14, 2008.

Second Quarter 2008 Financial Highlights

Revenues for the second quarter of 2008 were $8.59 million, up 35% year- over-year compared with $6.36 million reported in the second quarter of 2007. The increase in sales was driven mainly by the increase in sales of the Company's main product, Xuesaitong Soft Capsules, as well as the Company's non-prescription ("OTC") pharmaceutical products.

Gross profit for the three months ended June 30, 2008 was $5.60 million compared with $4.77 million in the same period last year. Gross margin was 65.2%, a decline from 75.1% in the second quarter of 2007. The decre
'/>"/>

SOURCE China Shenghuo Pharmaceutical Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. ChinaBio(R) Inaugural Partnering Forum Scheduled for June 2009 in Shanghai, China
2. China Documents First Case of Tick-Borne Disease Spread
3. Drug Information Association (DIA) Opens New Office In China
4. China Healthcare Acquisition Corp Agrees to Terminate Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd.
5. China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009
6. China Bio-Immunity Corporation to Report Third Quarter 2008 Financial Results
7. Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC
8. Measles Initiative Supports Disease Prevention for Children in Chinas Earthquake Zone
9. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
10. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
11. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008